Stockscreener 앱 받기
87.08
3.81%
-3.45
전일 마감가:
$90.53
열려 있는:
$90.11
하루 거래량:
275.31K
Relative Volume:
1.25
시가총액:
$1.28B
수익:
$1.30M
순이익/손실:
$-130.19M
주가수익비율:
-10.38
EPS:
-8.3898
순현금흐름:
$-131.94M
1주 성능:
-6.78%
1개월 성능:
-20.31%
6개월 성능:
+12.42%
1년 성능:
+153.29%
1일 변동 폭
$85.80
$92.45
1주일 범위
$85.80
$96.10
52주 변동 폭
$28.16
$155.29
인히브릭스 Stock (INBX) Company Profile
명칭
Inhibrx Biosciences Inc
전화
(858) 795-4220
주소
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
87.08 | 1.28B | 1.30M | -130.19M | -131.94M | -8.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
인히브릭스 Stock (INBX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-08-24 | 개시 | H.C. Wainwright | Buy |
| 2026-04-08 | 개시 | Stifel | Buy |
| 2024-07-23 | 개시 | JMP Securities | Mkt Perform |
| 2024-01-23 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | 개시 | SMBC Nikko | Outperform |
| 2021-09-21 | 개시 | JMP Securities | Mkt Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-09-14 | 개시 | Credit Suisse | Outperform |
| 2020-09-14 | 개시 | Evercore ISI | Outperform |
모두보기
인히브릭스 주식(INBX)의 최신 뉴스
Inhibrx Biosciences stock falls 1.62 percent on October 5 - AD HOC NEWS
Form 4 Inhibrx Biosciences Inc For: 28 September By Investing.com - Investing.com Nigeria
Inhibrx Biosciences CEO Mark Lappe buys $998k in company stock - Investing.com Canada
Form 4 Inhibrx Biosciences Inc For: 28 September By Investing.com - Investing.com India
Form 4 Inhibrx Biosciences Inc For: 28 September By Investing.com - Investing.com UK
Four purchases over two days: Inhibrx Biosciences (INBX) CEO's family trust bought 10,000 shares. - Stock Titan
Inhibrx Biosciences CEO Mark Lappe buys $998k in company stock - Investing.com
Inhibrx Biosciences director Jon Kayyem buys $500,000 in common stock By Investing.com - Investing.com Nigeria
Form 4 Inhibrx Biosciences Inc For: 23 September - Investing.com India
Inhibrx Biosciences director Jon Kayyem buys $500,000 in common stock - Investing.com India
Form 4 Inhibrx Biosciences Inc For: 23 September By Investing.com - Investing.com UK
At $100 a share, a director's family trust bought 5,000 shares of Inhibrx Biosciences (INBX). - Stock Titan
Inhibrx Biosciences Director Kristiina Vuori Receives Corrected Stock Option Grant - Kalkine Media
Inhibrx Biosciences Director Kimberly Manhard Revises Stock Option Grant Filing - Kalkine Media
Director at Inhibrx (NASDAQ: INBX) awarded 10,000 options - Stock Titan
Inhibrx (NASDAQ: INBX) director gets 10,000 options expiring 2036 - Stock Titan
Inhibrx (INBX) corrects director's 10,000-option grant - Stock Titan
Inhibrx (INBX) corrects 10,000-option grant to director - Stock Titan
Inhibrx Biosciences director Jon Kayyem buys $500,000 in stock - Investing.com
Family trust of Inhibrx (INBX) director adds 5,000 shares at $100 - Stock Titan
Director’s trust sells 1,500 Inhibrx (INBX) shares - Stock Titan
Director’s trust at Inhibrx (NASDAQ: INBX) logs four 500-share stock sales - Stock Titan
Inhibrx (NASDAQ: INBX) director's trust files to sell 500 shares - Stock Titan
Founder of Inhibrx Biosciences Mark Lappe Buys 2.7% More Shares - webull.com
Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock By Investing.com - Investing.com South Africa
Director trust at Inhibrx (INBX) proposes $55.9K stock sale - Stock Titan
Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock By Investing.com - Investing.com Australia
Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock By Investing.com - Investing.com UK
Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock - Investing.com
Inhibrx Biosciences Director Kimberly Manhard Sells 1,000 Shares via Revocable Trust in September 2026 - Kalkine Media
Director’s trust at Inhibrx Biosciences (INBX) sells 1,000 shares in two days - Stock Titan
Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), Inhibrx Biosciences Inc (INBX) and Circle Internet Group, Inc. Class A (CRCL) - The Globe and Mail
Founder of Inhibrx Biosciences Mark Lappe Buys 2.7% More Shares - simplywall.st
Founder of Inhibrx Biosciences Mark Lappe Buys 2.7% More Shares - simplywall.st
Inhibrx director Jon Kayyem buys $567,580 in company stock By Investing.com - Investing.com South Africa
Director-linked trust plans $57.9K INBX stock sale - Stock Titan
Inhibrx, Eikon rise after insider buying - TradingView
H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy - Investing.com
H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy By Investing.com - Investing.com Canada
Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom (NASDAQ:INBX) - Seeking Alpha
Inhibrx director Jon Kayyem buys $567,580 in company stock By Investing.com - Investing.com Australia
Inhibrx director Jon Kayyem buys $567,580 in company stock By Investing.com - Investing.com Canada
Inhibrx (INBX) investor files notice to sell 500 shares - Stock Titan
Family trust tied to Inhibrx (INBX) director buys more stock in open market - Stock Titan
Inhibrx Biosciences reports strong Phase 2 INBRX-106 data - TipRanks
Inhibrx (INBX) director buys 2,500 shares via family trust - Stock Titan
Inhibrx Biosciences (INBX) chief boosts stake with 25,000-share buy - Stock Titan
80% response in HPV+ head and neck cancer lifts Inhibrx (INBX) trial plans - Stock Titan
Why Inhibrx Biosciences (INBX) Stock Is Down Today - Quiver Quantitative
Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates - Benzinga
인히브릭스 (INBX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
인히브릭스 주식 (INBX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lappe Mark | Chief Executive Officer |
Sep 28 '26 |
Buy |
100.76 |
4,500 |
453,426 |
740,548 |
| Kayyem Jon Faiz | Director |
Sep 23 '26 |
Buy |
100.00 |
5,000 |
500,000 |
434,360 |
| Kayyem Jon Faiz | Director |
Sep 16 '26 |
Buy |
100.00 |
5,000 |
500,000 |
429,360 |
| MANHARD KIMBERLY | Director |
Sep 15 '26 |
Sale |
105.05 |
500 |
52,525 |
7,500 |
| MANHARD KIMBERLY | Director |
Sep 15 '26 |
Proposed Sale |
105.05 |
500 |
52,525 |
0 |
| MANHARD KIMBERLY | Director |
Sep 14 '26 |
Proposed Sale |
110.26 |
500 |
55,130 |
0 |
| MANHARD KIMBERLY | Director |
Sep 14 '26 |
Sale |
110.26 |
500 |
55,130 |
8,000 |
| MANHARD KIMBERLY | Director |
Sep 11 '26 |
Proposed Sale |
111.78 |
500 |
55,888 |
0 |
| MANHARD KIMBERLY | Director |
Sep 11 '26 |
Sale |
111.78 |
500 |
55,888 |
8,500 |
| MANHARD KIMBERLY | Director |
Sep 09 '26 |
Proposed Sale |
115.80 |
500 |
57,898 |
0 |
5.31%
자본화:
|
볼륨(24시간):